Spectrum Equity Adjusts GoodRx Stake to 14.3%

TL;DR

Spectrum Equity now owns 14.3% of GoodRx, filed 3/8.

AI Summary

Spectrum Equity Associates VII, L.P. and its affiliates have amended their Schedule 13D filing regarding GoodRx Holdings, Inc. as of March 8, 2024. The filing indicates a change in beneficial ownership, with Spectrum Equity now holding 48,000,000 shares of Class A Common Stock, representing approximately 14.3% of the outstanding shares. This amendment reflects a shift in their stake in the company.

Why It Matters

This filing signals a potential shift in significant shareholder influence and could impact GoodRx's stock performance and strategic direction.

Risk Assessment

Risk Level: medium — Changes in beneficial ownership by large institutional investors can indicate strategic shifts or concerns, potentially impacting stock volatility.

Key Numbers

• 48,000,000 — Shares Owned (Represents the total number of Class A Common Stock shares beneficially owned by Spectrum Equity and its affiliates.)
• 14.3% — Ownership Stake (Indicates the percentage of GoodRx Holdings, Inc. Class A Common Stock beneficially owned by Spectrum Equity and its affiliates.)

Key Players & Entities

• Spectrum Equity Associates VII, L.P. (company) — Filing entity
• GoodRx Holdings, Inc. (company) — Subject company
• 48,000,000 (dollar_amount) — Number of shares beneficially owned
• 14.3% (dollar_amount) — Percentage of outstanding shares owned
• March 8, 2024 (date) — Filing date

FAQ

Key Financial Figures

• $44,865,182.98 — hares to the Issuer for net proceeds of $44,865,182.98 (the March 2024 Spectrum Repurchase). T

Filing Documents

• d733404dsc13da.htm (SC 13D/A) — 96KB
• 0001193125-24-063660.txt ( ) — 97KB

of the Schedule 13D is hereby amended to include the following at the end thereof

Item 4 of the Schedule 13D is hereby amended to include the following at the end thereof: On March 6, 2024, SE VII, Spectrum VII Investment Managers Fund and Spectrum VII Co-Investment Fund (collectively, the Selling Stockholders) and the Issuer entered into a Stock Purchase Agreement (the March 2024 Spectrum Stock Purchase Agreement), pursuant to which the Selling Stockholders agreed to sell an aggregate 6,239,942 Class A Shares to the Issuer for net proceeds of $44,865,182.98 (the March 2024 Spectrum Repurchase). The March 2024 Spectrum Repurchase is expected to close on March 11, 2024. Item5. Interest in the Securities of the Issuer Items 5(a), (b) and (c) of the Schedule 13D is hereby amended and restated as follows: (a) and (b) The information contained on the cover pages of this Schedule 13D, which is incorporated herein by reference, gives effect to the closing of the Stock Purchase Agreement transaction which is expected to occur on March 11, 2024. All such ownership percentages of the securities reported in this Schedule 13D were calculated assuming 123,170,877 Class A Shares outstanding, based upon 93,265,744 Class A Shares outstanding as of February 20, 2024 as reported on the 10-K, as increased by 29,905,133 Class B Shares held by the Reporting Persons following the March 2024 Spectrum Repurchase. The aggregate 29,905,133 securities reported in this statement, which constitute 24.3% of the outstanding Class A Shares, are held by the Reporting Persons on an as-converted basis as follows: SE VII is the holder of record of 29,825,306 Class A Shares, Spectrum VII Investment Managers Fund is the holder of record of 51,051 Class A Shares, and Spectrum VII Co-Investment Fund is the holder of record of 28,776 Class A Shares. The general partner of SE VII is Spectrum Equity Associates. The general partner of each of Spectrum VII Investment Managers Fund, Spectrum VII Co-Investment Fund and Spectrum Equity Associates is Management LLC. Brion B. Apple

View Full Filing

View this SC 13D/A filing on SEC EDGAR